Supernus Pharmaceuticals reports Q3 financial results and provides 2026 full-year guidance
Supernus exceeded Q3 revenue estimates, achieving $129.2M, and raised its full-year 2026 adjusted EPS guidance to $5.60-$5.70. Strong performance in Parkinson's products drove the upward revision, bolstering confidence for the specialty neurology leader.
View filing at SEC.gov →